Search Results

Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Subtle Medical, Inc., a leading innovator in artificial intelligence -powered image acquisition, have entered into a global agreement in the field of magnetic resonance imaging.

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a pioneer in diagnostic imaging, is showcasing its commitment to innovation and purpose-driven partnership at the Radiological Society of North America (RSNA) 2023 Annual Meeting, to be held November 26-30 in Chicago, Illinois.

Bracco Imaging S.p.A. and SonoThera, Inc. have entered into an agreement under which Bracco Imaging will provide its cutting-edge gas-filled microbubbles technology platform to SonoThera for use in the development of its novel, ultrasound-guided nonviral gene therapy platform.

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., an innovative world leader in diagnostic imaging, announced the 2022 “Leaders on the Horizon” Residency Program recipients.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

Bracco Imaging SpA and BDP International have successfully completed a first-of-its-kind move for the Bracco Group.

Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announces that on December 7, 2023 the European Commission (EC) has granted the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union (EU).

Olympus announced a strategic co-marketing agreement with Monroe Township, N.J.-based Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business.

Bracco Imaging S.p.A. received notification that the CHMP of the EMA has adopted a positive opinion recommending approval of Vueway® solution for injection for magnetic resonance imaging for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging of the CNS and several body organs.